Promethera Biosciences Competitors and Similar CompaniesClear all
Intercept Pharmaceuticals's competitors and similar companies include Poxel.
 Intercept Pharmaceuticals Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. |  Poxel Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases. | |
Founding Date | Founding Date 2002 | Founding Date 2009 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations New York, US HQ Wien, AT Mississauga, CA Kongens Lyngby, DK Paris, FR München, DE Dublin, IE see more | Locations Lyon, FR HQ Chiyoda City, JP Cambridge, US |
Employees | Employees 58321% increase | Employees 6 |
Valuation ($) | Valuation ($) 794.7 m | Valuation ($) 18.3 m |
Financial | ||
Revenue (est.) | Revenue (est.) $285.7m (FY, 2022) | Revenue (est.) €6.6m (FY, 2024) |
Cost of goods | Cost of goods $984k (FY, 2022) | Cost of goods €2.8m (FY, 2024) |
Gross profit | Gross profit $284.7m (FY, 2022) | Gross profit €3.8m (FY, 2024) |
Net income | Net income $221.8m (FY, 2022) | Net income (€18.3m) (FY, 2024) |
Funding | ||
Total funding raised | Total funding raised $ 55m | Total funding raised $ 33.8m |
For sources of this data, please see the company profile
View Company Profiles
Poxel
HQ
Lyon, FR
Employees
6
Poxelis a research integrated pharmaceutical company that develops products for metabolic diseases.
View company